International Society for the Study of Women's Sexual Health

Flibanserin approved as the FIRST pharmacologic treatment option for women suffering from hypoactive sexual desire disorder

Dear ISSWSH members,

It is with tremendous excitement that we share the announcement that flibanserin, a drug for acquired, generalized hypoactive sexual desire disorder (HSDD) developed by Sprout Pharmaceuticals, was approved by the FDA on August 18, 2015. This follows the June 4, 2015 meeting of their Advisory Committee whose members voted 18-6 for approval.

This historic event marks the availability of the first pharmacologic treatment for women suffering from HSDD. We applaud the FDA for recognizing female sexual disorders as one of their top 20 conditions for which there is unmet medical need and for making their decision to approve flibanserin based on science. We are optimistic that this approval will stimulate more research and drug development for HSDD and other female sexual disorders for which therapeutic options are greatly needed.

We also extend robust gratitude to many of our leaders and members who played a critical role in this long awaited advancement in women’s health care. By serving on the FDA Advisory Panel, speaking for the sponsor at the FDA, testifying at the Open Public Hearings, and caring for patients who suffer from sexual disorders without approved medical treatment options, ISSWSH members provided broad expertise, invested countless hours, and contributed in many ways to this monumental leap forward in sexual medicine.

Flibanserin will be marketed with the trade name Addyi. As a multidisciplinary, scientific organization dedicated to research, clinical practice, and education, ISSWSH is poised to develop and disseminate clinical practice guidelines regarding screening, diagnosis, and management strategies for HSDD. Through our robust educational infrastructure, we will help to ensure appropriate, safe, and selective treatment of HSDD with Addyi, now that approval has finally arrived!

Most sincerely,

Sharon J. Parish, MD, IF, NCMP
ISSWSH President, 2014-2016

Sheryl A. Kingsberg, PhD, IF
Chair, ISSWSH Advocacy Committee

DOWNLOAD OUR PRESS RELEASE

Save the Date

ISSWSH Fall Course 2019
November 14-16, 2019   2 days left
DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...

ISSWSH Annual Meeting 2020
March 5-8, 2020   114 days left
Renaissance Orlando at Seaworld, Orlando, FL, USA

ISSWSH Sexual Pain Course 2020
April 17-18, 2020 114 days left
Georgetown University Medical Center, Medical and Dental Building, Washington, DC, USA

ISSWSH Annual Meeting 2021
March 4-7, 2021   478 days left
Renaissance Dallas Hotel, Dallas, TX, USA

Latest Tweets

Retrospective chart review shows that patients with vulvodynia do NOT have higher rates of infertility treatment co… https://t.co/Ri5nVIzNL9 ISSWSH
One of the biggest warnings when using Addyi for female HSDD is hypotension and syncope with alcohol consumption.… https://t.co/UNxsJIzI1J ISSWSH
Pessaries don’t preclude safe and satisfying sex https://t.co/CrcCYBSJRh ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on Twitter!